	US 12,109,232 B2
	Radiation/chemotherapy sensitizer to be used for intratumoral local injection and for controlled release of hydrogen peroxide with hydrogel as carrier
Yasuhiro Ogawa, Kochi (JP); Shiho Tokuhiro, Kochi (JP); Hideki Oda, Kochi (JP); Norikazu Yokota, Kochi (JP); and Ryo Akima, Kochi (JP)
Assigned to KORTUC INC., (JP)
Filed by KORTUC INC., Tokyo (JP)
Filed on May 24, 2021, as Appl. No. 17/328,865.
Application 17/328,865 is a continuation of application No. 14/767,939, abandoned, previously published as PCT/JP2014/053542, filed on Feb. 14, 2014.
Claims priority of application No. 2013-028413 (JP), filed on Feb. 15, 2013.
Prior Publication US 2021/0401881 A1, Dec. 30, 2021
Int. Cl. A61K 33/40 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 41/00 (2020.01); A61K 45/06 (2006.01); A61K 47/42 (2017.01); A61N 5/10 (2006.01)

CPC A61K 33/40 (2013.01) [A61K 9/0024 (2013.01); A61K 9/06 (2013.01); A61K 41/0038 (2013.01); A61K 45/06 (2013.01); A61K 47/42 (2013.01); A61N 5/10 (2013.01)]

7 Claims

1. A sensitizer comprising a combination of: (a) hydrogen peroxide at a concentration of 0.5 to 3.5 w/v % and (b) a hydrogel comprising a crosslinked gelatin gel prepared from a gelatin having an isoelectric point of 4.5 to 5, wherein the crosslinked gelatin gel is in a particulate form, the hydrogel is at a concentration of 0.5 to 10 w/v %, and the sensitizer is in an intratumoral injection form.